Illumina Inc

Pacific Biosciences

Short interest: 5.09% of float, squeeze risk: MODERATE

Dilution score: 18/100 (LOW), 24.0 months cash

1002 PubMed publications found for Illumina

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors.

Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.

Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation.

Efficacy and Safety of Ecopipam for Tourette Syndrome: A Phase 3 Randomized Clinical Trial.

Dilution score: 23/100 (LOW), 999.0 months cash

997 PubMed publications found for Illumina

Link between ultra-processed foods and drinks intake, gut microbiota and inflammation: an exploratory analysis in adult volunteers.

Evaluation of DNA extraction methods from clinical Mycobacterium tuberculosis primary liquid culture for whole-genome sequencing.

995 PubMed publications found for Illumina

Genomic analysis of Salmonella Typhi from a typhoid conjugate vaccine trial.

Short interest: 4.44% of float, squeeze risk: MODERATE

Dilution score: 26/100 (MEDIUM), 999.0 months cash

992 PubMed publications found for Illumina

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC).

993 PubMed publications found for Illumina

Emergence of Linezolid Resistance Genes optrA and poxtA in an Avian Enterococcus asini.

Short interest: 4.45% of float, squeeze risk: MODERATE

Congress: 1 buys, 0 sells (2 total trades)

SW convergence: 46/100 (Neutral), 1 bullish / 2 bearish signals

987 PubMed publications found for Illumina

Multi-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome.

Clinically actionable genomic and transcriptomic landscape of advanced neuroendocrine neoplasms.

A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations.

984 PubMed publications found for Illumina

Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer.

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

Short interest: 4.88% of float, squeeze risk: MODERATE

Congress: 0 buys, 0 sells (1 total trades)

SW convergence: 36/100 (Bearish Convergence), 0 bullish / 2 bearish signals

SW convergence: 37/100 (Bearish Convergence), 0 bullish / 2 bearish signals

981 PubMed publications found for Illumina

FOCU.SE trial: a nationwide Swedish drug repurposing protocol and research framework.

The role of the molecular tumor board: learnings from the ROME trial.

SW convergence: 42/100 (Bearish Convergence), 1 bullish / 3 bearish signals

978 PubMed publications found for Illumina

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.

Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor.

Short interest: 4.83% of float, squeeze risk: MODERATE

979 PubMed publications found for Illumina

<article class="bts-verified-summary" data-ticker="ILMN">
<p>Illumina Inc (ILMN) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>ILMN has 2 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-2">[2]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Illumina+Inc%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">SEC EDGAR · 0001110803 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22ILMN%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001110803

Illumina Inc (ILMN) — BioTechSigns Verified Summary

Illumina Inc (ILMN) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[1].

ILMN has 2 Form 4 insider filings recorded at the SEC in the past 30 days[2].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Illumina+Inc%22&aggFilters=status%3Arec%2Cact
[2] SEC EDGAR, 0001110803. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22ILMN%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

Prospective observational study to further understand the value that a multi-omic approach has in individuals with a multi system, early onset disorder that does not have a molecular diagnosis by whole genome sequencing.

iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disorders

This is a prospective, single-center, open-label study to investigate the diagnostic efficacy of the TruGenome CVD test and its impact on clinical management compared to usual care in individuals with cardiovascular disease. Diagnostic yield and changes of management (CoM) will be assessed both within the WGS group and compared to a contemporaneous, matched (2:1) usual care (UC) group sourced from EHR records.